跳至主要内容
临床试验/NCT00955461
NCT00955461已完成不适用

Post-Market, Randomized, Single Blind, Split-Faced Comparison of the RevLite Nd:YAG Laser System Versus a Non-Ablative, Mid Infra-red, Fractionated Type Laser System for Skin Rejuvenation

ConBio, a Cynosure Company1 个研究点 分布在 1 个国家目标入组 12 人开始时间: 2009年12月1日最近更新:
适应症

试验速览

阶段
不适用
状态
已完成
发起方
入组人数
12
试验地点
1
主要终点
Assessment of the percentage of overall, cumulative improvement from Baseline in the appearance of wrinkles, skin tone and/or texture, pigmentation and acne scars

研究概览

简要总结

The purpose of this study is to compare the results of treatment between the side of the face treated with the RevLite Laser and the side of the face treated with a fractionated laser system.

研究设计

研究类型
Interventional
分配方式
Na
干预模型
Single Group
主要目的
Treatment
盲法
Single (Outcomes Assessor)

入排标准

年龄范围
25 Years 至 65 Years(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Fitzpatrick Skin Type I-VI and Wrinkle Class I
  • Between the ages of 25-65
  • Evidence of bilateral dyschromia

排除标准

  • Pregnant, lactating, or is planning to become pregnant
  • history of cutaneous photosensitization, porphyria, hypersensitivity to porphyrins or photodermatosis
  • any skin pathology/condition that could interfere with evaluation or requires the use of interfering topical or systemic therapy
  • coagulation disorder or currently using anti-coagulation medication (including but not limited to heavy aspirin therapy)
  • any condition which, in the investigator's opinion, would make it unsafe for the subject to participate in the study
  • currently enrolled in an investigational drug or device trial, or has received an investigational drug or been treated with an investigational device within 30 days
  • unable to communicate or cooperate with the investigator due to language problems, poor mental development, or impaired cerebral function
  • unreliable for the study, including subjects who engage in excessive alcohol intake or drug abuse, or subjects who are unable to return for scheduled follow-up visits
  • Accutane within 6 months
  • need to be exposed to artificial tanning devices or excessive sunlight during the trial
  • prior treatment with parenteral gold therapy
  • Diabetes Type 1 or 2
  • does not agree to refrain from any other type of facial skin resurfacing (e.g., microdermabrasion, laser or IPL treatment, chemical peel) or injected fillers/other substances (e.g., Restylane, Botox) that might affect the treatment area for the duration of the study
  • artificial tanning within 1 month
  • (micro)dermabrasion within 3 months
  • other laser or IPL to the face within 6 months
  • chemical peel within 1 month
  • injectable fillers within 3 months
  • topical retinoids within 3 months
  • over-the-counter anti-aging products (e.g., those containing peptides, hyaluronic acid, or agents specifically advertised as having anti-aging or age-inhibiting properties) within 1 month
  • history of keloids or hypertrophic scarring
  • evidence of compromised wound healing
  • history of cold sores, chickenpox or shingles and unwilling to take a prophylactic course of Valtrex/acyclovir
  • allergy to acyclovir

结局指标

主要结局

Assessment of the percentage of overall, cumulative improvement from Baseline in the appearance of wrinkles, skin tone and/or texture, pigmentation and acne scars

时间窗: 3 and 6 months post final treatment

次要结局

未报告次要终点

研究者

发起方
ConBio, a Cynosure Company
申办方类型
Industry
责任方
Sponsor

研究点 (1)

Loading locations...

相似试验

Comparison of the RevLite Electro-optic Q-Switched... | 临床试验